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We show that knowledge of the phase behavior of a protein allows
one to create a rational screen that increases the success rate of
crystallizing challenging proteins. The strategy is based on using
microfluidics to perform large numbers of protein solubility ex-
periments across many different chemical conditions to identify
reagents for crystallization experiments. Phase diagrams were
generated for the identified reagents and used to design custom-
ized crystallization screens for every protein. This strategy was
applied with a 75% success rate to the crystallization of 12 diverse
proteins, most of which failed to crystallize when using traditional
techniques. The overall diffraction success rate was 33%, about
double what was achieved with conventional automation in large-
scale protein structure consortia. The higher diffraction success
rates are achieved by designing customized crystallization screens
using the phase behavior information for each target. The identi-
fication of reagents based on an understanding of protein solu-
bility and the use of phase diagrams in the design of individualized
crystallization screens therefore promotes high crystallization
rates and the production of diffraction-quality crystals.
microfluidics  protein phase behavior
One of the main bottlenecks in the application of proteincrystallography to large-scale structural biology efforts is the
production of diffraction-quality crystals. Protein crystallization
relies on the identification of reagents that promote crystal forma-
tion and an understanding of protein solubility in the presence of
these reagents to achieve optimal crystal growth. Traditional tech-
niques to identify reagents for crystallization include incomplete
factorial searches across chemical space and sparse-matrix screen-
ing around reagents previously shown to crystallize proteins (1, 2).
Although these techniques provide a starting point for crystalliza-
tion experiments, they are not designed around the biophysical
properties of individual proteins and have met with limited success
for more challenging crystallization targets. For example, the
National Institutes of Health Protein Structure Initiative (PSI) was
able to generate diffraction-quality crystals from less than one in
five of the 10,000 purified protein targets it has attempted to date
(http:targetdb.pdb.orgstatisticsTargetStatistics.html).
Knowledge of protein solubility in the presence of a crystal-
lizing reagent enables one to effectively use the reagent in a way
that will promote crystallization. The traditional method to study
protein solubility in response to reagents is to construct a phase
diagram that measures the solubility at different protein and
reagent concentrations. The protein solubility curve outlined in
each phase diagram depicts the most favorable protein and
reagent concentrations to use in a crystallization experiment for
optimal crystal growth. Currently, phase diagrams are only
generated for readily available model proteins and for proteins
with known crystallization conditions to improve crystal mor-
phology (3–12). The infrequent use of phase diagrams for
crystallization experiments is due to the large sample volumes
and time required to construct the diagrams. The general
utilization of phase diagrams to analyze protein solubility before
starting crystallization experiments would lead to a more phys-
ical and rational approach to protein crystallization.
Here, we show that a crystallization strategy based on a
detailed understanding of protein solubility increases the crys-
tallization success rate for challenging proteins. A microfluidic
formulator device was used to systematically screen hundreds of
reagents against protein targets at several points on the phase
diagrams to identify reagents that affect the solubility of the
protein. Next, each of the identified reagents was explored by
constructing a complete phase diagram outlining the solubility
limits of the protein in the presence of the reagent. The phase
diagrams were then used to design individualized crystallization
screens tailored to the solubility properties of the target protein.
This device was previously demonstrated to greatly enrich
crystallization conditions for xylanase, UMP kinase, and the
integral membrane protein SERCA (13, 14). The customized
crystallization screens were tested by using a redesigned free
interface diffusion screening device. Successful crystallization
conditions were transported to a larger-scale crystal growth
format for diffraction analysis.
We applied this rational screening strategy to the crystalliza-
tion of 12 biologically diverse and challenging proteins, 8 of
which failed to crystallize when using traditional techniques. The
crystallization targets range in size from 16 kDa to 360 kDa
complexes and include membrane proteins, large multiprotein
complexes, a proteinRNA complex, a metalloprotein complex,
metabolic proteins, and an extracellular matrix protein. Identi-
fication of reagents and phase diagram generation for each
target were completed by using only microliters of sample, and
we found that crystallization and diffraction success rates were
roughly double that obtained by the PSI when using conventional
automation. The increased success rates are noteworthy given
the target diversity and that 67% of the targets are from
eukaryotic sources while the PSI crystallization targets to date
are biased toward prokaryotic sources with only 30% of the
targets from eukaryotic sources (http:targetdb.pdb.org
statisticsTargetStatistics.html).
Results and Discussion
The phase diagram-based approach to protein crystallography
was used to design and implement customized crystallization
strategies for 12 challenging protein targets. To begin, protein
solubility was screened against an extensive set of chemical
conditions to identify suitable reagents for crystallization trials
(Fig. 1A). The solubility screening included a full factorial search
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of 448 reagents composed of unique precipitant, buffer, and salt
combinations. For each reagent, protein phase behavior was
explored by sampling protein solubility at six different protein
and precipitant concentrations across the phase diagram for a
total of 2,688 solubility experiments per target. The ability of
each reagent to manipulate protein solubility was quantified by
the amount of protein aggregation observed when the protein
was introduced to the reagent. Reagents that caused protein
aggregation above a threshold level were considered to be
potential crystallizing reagents for that target. The solubility
screening across chemical and phase space identified between 51
and 246 potential crystallizing reagents for each of the targets.
Trends in the solubility screening results indicate that protein
phase behavior was predominately controlled by the precipitat-
Fig. 2. Phase behavior characterization for targets. One complete phase diagram is shown for each target. (A) bR D85S with 0.125 M potassium acetate, 0.1
M sodium citrate (pH 6.5), and PEG 1500. (B) bR with 0.125 M ammonium chloride, 0.1 M sodium acetate (pH 4.5), and PEG 1500. (C) Cbb3 with 0.075 M sodium
acetate, 0.1 M sodium citrate (pH 6.5), and PEG 1500. (D) AlaRS with 0.1 M magnesium sulfate, 0.1 M sodium citrate (pH 5.5), and PEG 5000 MME. (E) Fis1 with
0.1 M ammonium acetate, 0.1 M TrisHCl (pH 8.5), and PEG 8000. (F) P450 1–12G with 0.2 M ammonium sulfate, 0.1 M imidazole (pH 7.5), and PEG 8000. (G)
SMCScpA with 0.05 M magnesium sulfate, 0.1 M sodium citrate (pH 5.5), and PEG 2000 MME. (H) P2X with 0.3 M sodium acetate, 0.1 M Hepes (pH 7.5), and PEG
1500. (I) AMG with 0.5 M sodium chloride, 0.1 M TrisHCl (pH 8.5), and PEG 8000. (J) VCPVimp with 0.4 M ammonium acetate, 0.1 M sodium citrate (pH 6.5), and
PEG 1500. (K) TfTfR with 0.2 M ammonium sulfate, 0.1 M Hepes (pH 7.5), and PEG 1500. (L) 19S Lid with 0.1 M ammonium chloride, 0.1 M sodium citrate (pH
5.5), and PEG 5000 MME. Each phase diagram screened protein solubility at 72 different precipitant and protein concentrations. The blue points represent
concentrations where the protein is soluble, and the yellow points represent concentrations where the protein is insoluble.
Fig. 1. Solubility information for protein targets. (A) Solubility screening results for 12 protein targets. Pixel intensity standard deviation represents the amount
of protein aggregation seen in response to each reagent. The proteins are displayed from top to bottom in the order of decreasing protein aggregation: bR D85S,
bR, Cbb3, AlaRS, Fis1, P450 1–12G, SMCScpA, P2X, AMG, VCPVimp, TfTfR, and 19S Lid. The solubility screening results are grouped by precipitating agent and
are further subdivided by buffering agent. SeeMaterials andMethods for a list of the reagents screened. (B) Classification of identified reagents by the molecular
weight of the precipitating agent. (C) Classification of identified reagents by the deviation from the pI of the protein targets. (D) Classification of identified
reagents by the ionic strength of the solution. (E) Classification of the identified reagents by the anion component of the reagent. The anions acetate and tartrate
are abbreviated as Ace and Tar, respectively. (F) Classification of the identified reagents by the cation component of the reagent. (G) Comparison of the target
molecular weight and the identified reagents for each target. For B–G, the percentage of identified reagents is normalized by the number of reagents screened
in each category.
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ing component of the reagent (Fig. 1B). The effectiveness of each
of the reagent components on protein aggregation was deter-
mined by comparing the solubility results of reagents with two of
the three components held constant. The precipitants used in the
solubility experiments are polyethylene glycol (PEG) polymers
with different chain lengths and end groups, giving each PEG
polymer unique volume exclusion properties. Since the volume
exclusion effect is more significant in longer polymers because
of their larger radius of gyration, the longer polymers were used
at a lower concentration than the shorter polymers. Polymers of
four different chain lengths were examined, and for every target
the number of potential reagents identified with longer polymers
surpassed the number of reagents identified with shorter poly-
mers. Additionally, a second PEG polymer with a modified
monomethyl ether (MME) end group was screened at each
polymer length; the MME polymers produced fewer identified
reagents at each polymer length. Therefore, increasing the
polymer chain length of the precipitating agent increases the
protein aggregation response, and the polymer chemical com-
position also influences protein aggregation.
The solubility screening results also show that reagents with a
pH value in the vicinity of the theoretical isoelectric point (pI)
of the targets were identified as potential reagents with a slightly
higher frequency than reagents that deviated from the target pI
values (Fig. 1C). This increased identification of reagents is
consistent with the reduced intermolecular electrostatic repul-
sion of proteins near their pI. The variation in the identified
reagents at different pH values was moderate in comparison with
the variations seen for precipitant composition. The ionic
strength of the salt solutions used in the solubility screening
exhibited the expected trend of increased identified reagents at
higher ionic strengths (Fig. 1D). Although ionic strength had a
small influence on the identified reagents, no trends were
observable for the ionic composition of the reagents (Fig. 1E-F).
The ions are displayed by increasing protein aggregation
strength based on the Hofmeister series, and little variation in
the identified reagents is seen for the cation or anion compo-
nents of the reagent (15). A trend is also evident between the
decreasing molecular weight of the target and an increasing
number of identified reagents (Fig. 1G).
Fig. 3. Crystallization by using phase behavior information. Nine of the 12 targets were crystallized in free interface diffusion screening devices. (A) VCPVimp
rhombohedral crystals were grown in 0.44 M sodium chloride, 0.1 M sodium citrate (pH 6.0), and 6% PEG 1500. (B) bR rod crystals were grown in 0.25 M ammonium
chloride, 0.1 M sodium acetate (pH 4.5), and 35% PEG 1500. (C) bR D85S rod crystals were grown in 0.125 M potassium acetate, 0.1 M sodium citrate (pH 6.5),
and 35% PEG 1500. (D) Fis1 crystals were grown in 0.1 M ammonium acetate, 0.1 M TrisHCl (pH 8.5), and 20% PEG 8000. (E) 19S Lid rectangular prism crystals
were grown in 0.15 M sodium acetate, 0.1 M sodium citrate (pH 5.5), and 15% PEG 8000. (F) P450 1–12G plate crystals were grown in 0.28 M ammonium sulfate,
15% 1,3-propanediol, 0.1 M imidazole (pH 7.5), and 30% PEG 8000. (G) AlaRS crystals were grown in 0.15 M magnesium sulfate, 0.1 M sodium citrate (pH 5.5),
and 15% PEG 5000 MME. (H) SMCScpA crystals were grown in 0.05 M magnesium acetate, 0.1 M sodium citrate (pH 5.5), and 60% PEG 550 MME. (I) Cbb3
hexagonal crystals were grown in 0.125 M sodium chloride, 0.1 M sodium citrate (pH 6.5), and 15% PEG 1500. (J) Classification of crystal hits by the molecular
weight of the precipitating agent in the reagent, the deviation of the reagent from the pI of the protein targets, the ionic strength of the reagent, and the ionic
component of the reagent. The percentage of crystal hits is normalized by the number of reagents screened in each category. (Scale bars, 100 m.)
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Protein phase behavior was further characterized by the
generation of complete phase diagrams for a subset of the
reagents identified during the solubility screening. Empirically
determined solubility boundaries allow for the selection of
precipitant and protein concentrations that maximize the chance
of successful crystallization by excluding areas of phase space
that lie far into the precipitation or soluble regions. The com-
plete phase diagrams were produced by combining protein and
reagent at 72 different protein and precipitating agent concen-
trations across the phase diagram and measuring protein aggre-
gation at each position (Fig. 2). Positions where the protein
aggregated above a threshold level were classified as insoluble,
and positions where the protein did not aggregate above a
threshold value were classified as soluble. The phase diagrams
were used to design free interface diffusion experiments that
target the solubility boundary of the protein with each reagent.
For example, the phase diagram shown in Fig. 2A suggests that
targeting the position corresponding to 6 mgml bR D85S and
20% (wtvol) PEG 1500 would promote crystallization. A free
interface diffusion experiment targeting this position requires
combining 12 mgml bR D85S with 40% (wtvol) PEG 1500 at
a 1:1 protein to reagent ratio. As the free interface diffusion
experiment proceeds, the trajectories for each solution will
evolve to reach the desired position and promote protein crys-
tallization (see figure 3 in ref. 16 for details). Customized
crystallization conditions were designed by using this technique
for the specific reagents identified for each of the targets.
Crystallization experiments were carried out with the individ-
ualized rational screens by using a redesigned free interface
diffusion screening device (16). Each of the crystallization
conditions was tested against the protein at five different mixing
ratios to completely sample the solubility boundary of the
associated phase diagram (see Materials and Methods for de-
tails). Free interface diffusion experiments with the rational
screens resulted in a 75% crystallization success rate for the
proteins, whereas previous crystallization attempts in the labs of
collaborators failed to identify crystallization conditions for the
majority of the samples (Fig. 3). For the successfully crystallized
proteins, between 12% and 79% of the reagents screened
produced crystals. The targets were bimodal in their crystalli-
zation success rates; the majority of the targets crystallized for
a small subset of the reagents screened while the remaining
targets crystallized for the majority of the reagents screened.
The crystallization results show that the crystal hits fall within
a well defined region of precipitant and pH (Fig. 3J). Among the
precipitants used for crystallization experiments, more crystal
hits occurred with larger precipitants, and no crystal hits were
identified for the smallest precipitants. In contrast to the ob-
served protein aggregation trends, more crystal hits were iden-
tified with the chemically modified MME precipitants for the
larger precipitants. Although the variation in pH was larger,
more crystal hits were identified from reagents near the pI value
of the targets. No trend is observed in the number of crystal hits
and the ionic strength of the reagent. As was observed for the
protein aggregation results, the variation in crystal hits based on
the ion identity of the reagent is small with no apparent trends.
Various crystal morphologies appeared in response to different
reagents, including rectangular prism crystals, rhombohedral crys-
tals, hexagonal crystals, rod crystals, plates, needles, dendrites, and
spherulites. Optimization of the initial crystallization results with
additional free interface diffusion experiments improved crystal
size and morphology. The best crystallization conditions for each
target were transported to larger experimental formats to generate
crystals large enough for diffraction analysis (Fig. 4). The crystal-
lization conditions were translated to scale-up diffraction devices
(17), vapor diffusion format, or microbatch format with a 67%
success rate. Successful translation to larger formats was also clearly
correlated with the crystal quality attainable in the smaller format
crystallization experiments.
Diffraction experiments were performed on the crystals
grown in larger formats to evaluate the quality of the crystals. Of
the six crystals successfully transported to larger formats for
diffraction studies, 67% of these crystals produced diffraction
data (Fig. 5). This corresponds to a 33% overall success rate of
starting with purified protein and finishing with diffraction-
quality crystals. The membrane proteins diffracted to between
6.7 Å and 16 Å, and the metabolic protein diffracted to 3.7 Å
with a centered monoclinic unit cell of dimensions a  19.9 Å,
b  62.2 Å, c  188.7 Å,   90°,   118.91°, and   90°.
A point of concern is that although this method is highly
successful at generating diffraction-quality crystals, the diffrac-
tion resolution has not been high enough to solve the structures.
In contrast, the PSI has been quite successful in transitioning
from diffraction-quality crystals to solved structures. Reasons
for this discrepancy could include the inherent crystallization
difficulty of the targets we attempted, quality control on the
protein production side, and a lack of target optimization by the
systematic truncation of floppy subunits. Additionally, further
optimization of the crystal growth conditions by using tools such
as small-molecule additive screening or temperature control
Fig. 4. Larger-format crystals for diffraction analysis. Initial hits for six of the
nine targets were transported to a larger-scale growth format. (A) bR rod
crystals were grown in scale-up diffraction devices with 0.1 M potassium
sodium tartrate, 0.1 M sodium acetate (pH 4.5), and 35% PEG 1500. (B) bR D85S
rod crystals were grown in scale-up diffraction devices with 0.1 M sodium
nitrate, 0.1 M sodium citrate (pH 6.5), and 25% PEG 1500. (C) Cbb3 hexagonal
crystals were grown in scale-up diffraction devices with 0.15 M ammonium
acetate, 0.1 M sodium citrate (pH 5.5), and 30% PEG 1500. (D) VCPVimp
rhombohedral crystals were grown in scale-up diffraction devices with 0.4 M
sodium chloride, 0.1 M sodium citrate (pH 6.5), and 10% PEG 1500. (E) P450
1–12G plate crystals were grown by using vapor diffusion with 0.3 M ammo-
nium sulfate, 0.1 M imidazole (pH 7.8), and 28% PEG 8000. (F) 19S Lid
rectangular prism crystals were grown in microbatch with 0.175 M sodium
acetate, 0.1 M sodium citrate (pH 5.5), and 14% PEG 8000. (Scale bars, 100m.)
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could improve the diffraction resolution of the crystals. The
crystal optimization efforts were directly proportional to the
limited amount of material provided for each of the targets.
Our success rates of 75% for crystallization and 33% overall rate
of producing diffraction-quality crystals from purified protein are
roughly double those of the PSI, which are 38% and 18%, respec-
tively (http:targetdb.pdb.orgstatisticsTargetStatistics.html).
One must, however, also take into account the relatively small
sample size in the present survey (N  12) compared with the
large number (N  10,000) tested by the PSI, which leads to a
lower statistical significance in our observed rates. We have tried
to mitigate this effect by choosing protein targets that are well
above average in their crystallization difficulty; the vast majority
of our targets failed conventional crystallization attempts. The
size of the present data set notwithstanding, we believe the
evidence is strong enough to suggest that microfluidic crystal-
lization tools should become incorporated in large-scale struc-
tural genomics efforts.
In conclusion, the rational phase diagram-based crystalliza-
tion strategy presented in this article was successfully used to
crystallize diverse and challenging proteins. The use of solubility
information to design customized crystallization screens doubled
the crystallization success rate over traditional screening tech-
niques and increased the production of diffraction-quality crys-
tals. Microfluidic devices such as these consume small amounts
of protein, are inexpensive, and are amenable to use in high-
throughput crystallization efforts.
Materials and Methods
Protein Preparation. Protein samples were provided by the fol-
lowing collaborators: 98-kDa Aquifex aeolicus alanyl-tRNA syn-
thetase (AlaRS) at 15 mgml was from Manal Swairjo (The
Scripps Research Institute); 22-kDa human amelogenin (AMG)
at 2 mgml was from Stefan Habelitz (University of California,
San Francisco); 27-kDa Halobacteria bacteriorhodopsin (bR)
and bacteriorhodopsin mutant D85S (bR D85S) at 18 mgml
were from Marc Facciotti and Lee Hood (Institute for Systems
Biology); 126-kDa Rhodobacter sphaeroides cytochrome cbb3
(Cbb3) at 10 mgml was from Michael Merckel (University of
Helsinki); 16-kDa Saccharomyces cerevisiae Fis1 at 60 mgml was
from Takumi Koshiba and David Chan (California Institute of
Technology); 360-kDa Saccharomyces cerevisiae proteasome 19S
Lid particle (19S Lid) at 25 mgml was from Xavier Ambroggio,
Douglas Rees, and Raymond Deshaies (California Institute of
Technology); 45-kDa Mus musculus P2X at 6 mgml was from
Pavel Strop and Axel Brunger (Stanford University); 54-kDa
heme domain of Bacillus subtilis cytochrome P450 mutant 1–12G
(P450 1–12G) at 30 mgml was from Matthew Peters, Peter
Meinhold, and Frances Arnold (California Institute of Technol-
ogy); 123-kDaAquifex aeolicus SMCScpA complex at 22 mgml
was from Scott Gradia and James Berger (University of Cali-
fornia, Berkeley); 72-kDa human tranferrintransferrin receptor
mutant complex (TfTfR) at 27 mgml was from Anthony
Giannetti and Pamela Bjorkman (California Institute of Tech-
nology); and 254-kDa Rattus norvegicus VCP-97Vimp complex
(VCPVimp) at 10 mgml was from Byron DeLaBarre and Axel
Brunger (Stanford University).
Solubility Screening and Phase Diagram Generation. Solubility ex-
periments were performed by using a microfluidic formulator
device developed by Hansen et al. (2004). Device fabrication,
automation, experimental setup, and data acquisition were
previously described (13). The formulator device was used to
create 448 unique reagents for solubility screening by system-
atically combining 14 salt solutions, 4 buffering agents, and 8
precipitating agents. The salt solutions used were 4 M ammo-
nium acetate, 3 M sodium acetate, 5 M ammonium chloride, 5
M sodium chloride, 2 M potassium sodium tartrate, 4 M
ammonium sulfate, 7 M sodium nitrate, 2 Mmagnesium acetate,
2 Mmagnesium chloride, 2 Mmagnesium sulfate, 5 M potassium
acetate, 3 M potassium chloride, 2 M potassium phosphate, and
4 M sodium phosphate. The buffering agents used were 1 M
sodium acetate (pH 4.5), 1 M sodium citrate (pH 6.5), 1 M
TrisHCl (pH 8.5), and 1 M 3-(cyclohexylamino)-1-propanesul-
fonic acid (pH 10.5). The precipitating agents used were 100%
(wtvol) PEG 300, 100% (wtvol) PEG 350 MME, 100%
(wtvol) PEG 550MME, 50% (wtvol) PEG 1500, 50% (wtvol)
PEG 2000 MME, 50% (wtvol) PEG 3350, 50% (wtvol) PEG
5000 MME, and 50% (wtvol) PEG 8000. Salt solutions and
precipitating agents were used near the maximal solubility and
viscosity levels of each species. Each of the reagents was tested
against the protein targets at six different protein and precipitant
concentrations across the boundary of the phase diagram while
holding the salt solution and buffering agent at a fixed level. The
salt solutions were used at final concentration of 2.5% of the
stock solutions (0.05–0.175 M; see above), and the buffering
agents were used at a final concentration of 0.1 M. The six points
tested were (i) 80% precipitating agent and 2.5% protein, (ii)
67.5% precipitating agent and 15% protein, (iii) 52.5% precip-
itating agent and 30% protein, (iv) 37.5% precipitating agent and
45% protein, (v) 22.5% precipitating agent and 60% protein, and
(vi) 7.5% precipitating agent and 75% protein. A total of 2,688
solubility experiments were performed for each protein target.
Protein aggregation was quantified by imaging the protein in
solution with each reagent using a charge-coupled device cam-
era, calculating the pixel intensity standard deviation, and sub-
tracting the background pixel intensity standard deviation of the
reagent in the absence of protein. Reagents that caused the
protein to aggregate above 3 pixel intensity standard deviation
Fig. 5. Diffraction images of larger-format crystals. (A) P450 1–12G crystals
were harvested by using 25% ethylene glycol as a cryoprotectant and dif-
fracted to 3.7 Å. The unit cell is centered monoclinic with dimensions a 219.9
Å, b  62.2 Å, c  188.7 Å,   90°,   118.91°, and   90°. (B) Diffraction
data for Cbb3 crystals were collected at room temperature by using scale-up
diffraction devices, and the crystals diffracted to 14.5 Å. (C) Diffraction data
for bR D85S crystals were collected through scale-up diffraction devices by
using 20% glycerol as a cryoprotectant, and the crystals diffracted to 6.7 Å. (D)
bR crystals grown in scale-up diffraction devices were harvested by using 15%
PEG 1500 as a cryoprotectant and diffracted to 16 Å.
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units for at least one of the six points tested were classified as
potential crystallization reagents. For 3.3% of the images, the
pixel intensity standard deviation value was negative because of
errors in the formulator device, and for these measurements the
pixel intensity standard deviation was set to zero.
Complete phase diagrams were generated for a subset of the
crystallizing reagents identified with the solubility screening. For
each phase diagram, the reagent was combined with the protein
at 72 different precipitant and protein concentrations. The
protein concentration was tested between 5% and 80%, and the
precipitant concentration was tested between 2.5% and 77.5%.
Again, buffering agent and salt solution concentrations were
held constant throughout the phase diagram at the concentra-
tions listed above for the solubility screening. Protein aggrega-
tion was measured at each point as described above. Positions on
the phase diagram that caused the protein to aggregate above 3
pixel intensity standard deviation units were classified as insol-
uble, and positions below 3 were classified as soluble.
Crystallization Experiments and Device Fabrication. Initial crystalli-
zation experiments were performed by using a modified version
of the microfluidic free interface diffusion screening device (16).
The screening device design was modified to perform five free
interface diffusion experiments per reagent instead of three. The
protein:reagent mixing ratios used were 1:4, 1:2, 1:1, 2:1, and 4:1,
with a total reaction volume of 25 nl per free interface diffusion
experiment. One screening device was used to test 48 reagents
for a total of 240 parallel free interface diffusion experiments.
The previous design used a hybrid glasselastomer device and
was modified to consist solely of elastomer to facilitate faster
fabrication. The devices were fabricated by using multilayer soft
lithography (18). Two negative master molds were fabricated for
the control structures and for the flow structures with photore-
sist by using conventional lithography techniques. The 20-m-
thick control structures were fabricated by spinning photoresist
(MicroChem SU-8 2025) onto a silicon wafer at 3,000 rpm for
75 s and patterned by using a negative high-resolution transpar-
ency mask printed at 101.5% of the desired device size. For the
flow structures, the 13-m-thick reaction channels were fabri-
cated by spinning photoresist (Shipley SPR 220-7) onto a second
silicon wafer at 1,300 rpm for 70 s and patterned by using a
positive high-resolution transparency mask. The reaction chan-
nels were rounded by annealing at 180°C for 1 h. Next, the
45-m-thick reaction chambers were fabricated on top of the
reaction channels by spinning photoresist (MicroChem SU-8 50)
onto the second silicon wafer at 2,000 rpm for 45 s and patterned
by using a negative high-resolution transparency mask.
Elastomeric devices were created by pouring silicone elas-
tomer (General Electric RTV 615; 5 parts A:1 part B) onto the
flow structures to 1-cm thickness and by spinning elastomer (20
parts A:1 part B) at 2,000 rpm for 60 s onto the control structures
for a thickness of 30 m. The flow layer and the control layer
were partially cured at 80°C for 60 min and 40 min, respectively,
before the flow layer was peeled off of the flow mold and aligned
to the control layer. After the aligned device was cured for an
additional 1.5 h, the device was removed from the control mold
and the control and flow ports were punched with 20- and
14-gauge punching tools (Technical Innovations), respectively. A
blank layer of elastomer (20 parts A:1 part B) was spun at 2,000
rpm for 60 s on a blank silicone wafer and partially cured for 30
min at 80°C. The aligned device was bonded onto the blank layer
overnight at 80°C, and the device was completed by removal
from the blank silicone wafer and placement on a glass micro-
scope slide (Corning).
The crystallization experimental setup is described in ref. 16.
Crystal hits were verified by using IZIT protein stain, the crush
test, or diffraction analysis. Crystal hits were transported to
microfluidic scale-up diffraction devices, vapor diffusion format,
or microbatch format for diffraction experiments. Device fab-
rication and experimental setup with the scale-up diffraction
device is described in ref. 17. Scale-up diffraction devices were
incubated at room temperature up to 2 weeks, and cryopro-
tectant was introduced by diffusion 24 h before flash-freezing the
crystals in the devices. For vapor diffusion experiments, 1 l of
protein was combined with 1 l of reagent and suspended over
500 l of reagent and incubated at room temperature up to 2
weeks. For microbatch experiments, a layer of paraffin oil was
place over the microbatch wells, and 1 l of protein was
combined with 1 l of reagent under the oil and incubated at
room temperature up to 2 weeks. For vapor diffusion and
microbatch experiments, the crystals were looped from the
drops and through cryoprotectant before flash-freezing in liquid
nitrogen.
Diffraction Studies. Diffraction data for Cbb3 were collected at
station 11.1 of the Stanford Linear Accelerator Center (Stanford
University), at an incident wavelength of 1.0 Å with a 15-s
exposure and 1° oscillation. Diffraction data for bR and bRD85S
were collected at station 8.3.1 of the Advanced Light Source
(Lawrence Berkeley National Laboratory), at an incident wave-
length of 1.0 Å with a 20-s exposure and 1° oscillation. Diffrac-
tion data for P450 1–12G were collected on an R-axis IV
(California Institute of Technology) at an incident wavelength of
1.54 Å with a 30-min exposure and 1° oscillation.
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